Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. CRISPR Therapeutics AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -213.34%.
The historical rank and industry rank for CRISPR Therapeutics AG's ROC (Joel Greenblatt) % or its related term are showing as below:
LTS:0VRQ'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -850.94 Med: -172.62 Max: 184.43
Current: -253.25
During the past 12 years, CRISPR Therapeutics AG's highest ROC (Joel Greenblatt) % was 184.43%. The lowest was -850.94%. And the median was -172.62%.
LTS:0VRQ's ROC (Joel Greenblatt) % is ranked better than 52.15% of 1323
companies
in the Biotechnology industry
Industry Median: -296.6
vs LTS:0VRQ: -253.25
CRISPR Therapeutics AG's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.
CRISPR Therapeutics AG (LTS:0VRQ) ROC (Joel Greenblatt) % Explanation
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
CRISPR Therapeutics AG ROC (Joel Greenblatt) % Related Terms
CRISPR Therapeutics AG ROC (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for CRISPR Therapeutics AG's ROC (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CRISPR Therapeutics AG ROC (Joel Greenblatt) % Chart
LTS:0VRQ vs ORKA, TVTX, MANE: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, CRISPR Therapeutics AG's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CRISPR Therapeutics AG ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where CRISPR Therapeutics AG's ROC (Joel Greenblatt) % falls into.
CRISPR Therapeutics AG ROC (Joel Greenblatt) % Calculation
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -213.34% mean?
CRISPR Therapeutics AG (LTS:0VRQ) has a ROC (Joel Greenblatt) % of -213.34% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CRISPR Therapeutics AG and its competitors. According to the industry distribution chart, CRISPR Therapeutics AG ranks #633 out of 1323 companies in the Biotechnology industry, placing it in the top 47.8%.
Is CRISPR Therapeutics AG's ROC (Joel Greenblatt) % too high?
CRISPR Therapeutics AG's current ROC (Joel Greenblatt) % is -213.34%. Based on the distribution chart, CRISPR Therapeutics AG ranks #633 out of 1323 companies in the Biotechnology industry, which is above the industry midpoint. Overall, CRISPR Therapeutics AG has a GF Score™ of 45/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's ROC (Joel Greenblatt) % compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #633 out of 1323 companies for ROC (Joel Greenblatt) %. This puts CRISPR Therapeutics AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on CRISPR Therapeutics AG and its competitors. CRISPR Therapeutics AG's current ROC (Joel Greenblatt) % is -213.34%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (LTS:0VRQ) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.59, compared to a current price of $50.69 — trading 1312% above its estimated fair value. The current ROC (Joel Greenblatt) % is -213.34%. CRISPR Therapeutics AG's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For CRISPR Therapeutics AG (LTS:0VRQ), the current ROC (Joel Greenblatt) % is -213.34% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CRISPR Therapeutics AG (LTS:0VRQ) Overvalued in 2026?
Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued.
The current stock price of $50.69 is trading 1312% above its estimated GF Value™ of $3.59.
GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.
Key valuation signals for LTS:0VRQ:
ROC (Joel Greenblatt) %: -213.34%
GF Value™: $3.59 vs. price of $50.69 (1312% above fair value)
No single metric tells the full story. See the LTS:0VRQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
45GF Score
Get the complete analysis for LTS:0VRQ
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VRQ has been successfully added to your 
